Natera Inc (NTRA)

Add to Watchlists
Create an Alert
Quickflows
85.00 -5.59  -6.17% NASDAQ May 11, 08:40 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All NTRA News

News

View All Events

Events

Date Type Description
08/05/2021 00:00 Earnings Results Q2 2021 Earnings Results
08/05/2021 16:30 Earnings Calls Q2 2021 Earnings Call
05/06/2021 00:00 Earnings Results Q1 2021 Earnings Results
05/06/2021 16:30 EDT Earnings Calls Q1 2021 Earnings Call
02/25/2021 00:00 Earnings Results Q4 2020 Earnings Results
02/25/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 00:00 Earnings Results Q3 2020 Earnings Results
11/05/2020 16:30 EST Earnings Calls Q3 2020 Earnings Call
08/05/2020 16:30 EDT Earnings Calls Q2 2020 Earnings Call
08/05/2020 00:00 Earnings Results Q2 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 449.31M
Total Expenses (TTM) 693.73M
Net Income (TTM) -258.22M

Balance Sheet View Statement

Total Assets (Quarterly) 893.51M
Total Liabilities (Quarterly) 521.07M
Shareholders Equity (Quarterly) 372.44M

Cash Flow Statement View Statement

Cash from Operations (TTM) -222.29M
Cash from Investing (TTM) -288.21M
Cash from Financing (TTM) 501.59M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services include Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.
  • URL: https://www.natera.com
  • Investor Relations URL: http://investor.natera.com/phoenix.zhtml?c=254055&p=irol-irhome
  • HQ State/Province: Texas
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 05, 2021
  • Last Earnings Release: May. 06, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 85.00
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 5.38%
AOFCX Alger Small Cap Focus C 4.78%
WGFCX Wells Fargo Growth C 2.42%
LADQX Lord Abbett Developing Growth R2 1.78%
JGLYX JPMorgan Small Cap Growth R4 1.74%
ASG Liberty All-Star Growth 1.68%
DCCRX Delaware Small Cap Core R 1.29%
FKBSX Federated Hermes Kaufmann Small Cap B 1.04%
IWO iShares Russell 2000 Growth ETF 0.53%
VTWG Vanguard Russell 2000 Growth ETF 0.52%
VTWO Vanguard Russell 2000 ETF 0.27%
IWM iShares Russell 2000 ETF 0.27%

Comparables

Edit
EXAS Exact Sciences Corp
ILMN Illumina Inc
LNTH Lantheus Holdings Inc
GH Guardant Health Inc
CSTL Castle Biosciences Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.